¹US Oncology, Dallas, TX, USA

²Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA

³Onyx Pharmaceuticals, Richmond, CA, USA

⁴Warner-Lambert Corporation, Ann Arbor, MI, USA

⁵Imperial Cancer Research Fund and Imperial College School of Medicine, London, UK

Correspondence to: J Nemunaitis, US Oncology, 3535 Worth Street, Collins Bldg, 5th Floor, Dallas, Texas 75246, USA

Although genetically engineered adenoviruses hold promise for the treatment of cancer, clinical trial reports have utilized intratumoral injection to date. To determine the feasibility of intravenous delivery of ONYX-015, an E1B-55kD gene-deleted replication selective adenovirus with demonstrated clinical safety and antitumoral activity following intratumoral injection, we performed a clinical trial in patients with metastatic solid tumors. ONYX-015 was infused intravenously at escalating doses of 2 ´ 10¹⁰ to 2 ´ 10¹³ particles via weekly infusion within 21-day cycles in 10 patients with advanced carcinoma metastatic to the lung. No dose-limiting toxicity was identified. Mild to moderate fever, rigors and a dose-dependent transient transaminitis were the most common adverse events. Neutralizing antibody titers significantly increased within 3 weeks in all patients. IL-6, -IFN, TNF- and IL-10 increased within 24 h following treatment. Evidence of viral replication was detectable in three of four patients receiving ONYX-015 at doses 2 ´ 10¹² particles and intratumoral replication was confirmed in one patient. In conclusion, intravenous infusion of ONYX-015 was well tolerated at doses up to 2 ´ 10¹³ particles and infection of metastatic pulmonary sites with subsequent intratumoral viral replication was seen. The intravenous administration of genetically altered adenovirus is a feasible approach. Gene Therapy (2001) 8, 746-759.

ONYX-015; adenovirus; replication